|
[1]
|
中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018 [J]. 中华心力衰竭和心肌病杂志(中英文), 2018, 2(4): 196-225.
|
|
[2]
|
Hao, G., Wang, X., Chen, Z., et al. (2019) Prevalence of Heart Failure and Left Ventricular Dysfunction in China: The China Hy-pertension Survey, 2012-2015. European Journal of Heart Failure, 21, 1329-1337. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Lee, D.S., Gona, P., Vasan, R.S., Larson, M.G., Benjamin, E.J., Wang, T.J., Tu, J.V. and Levy, D. (2009) Relation of Disease Pathogenesis and Risk Factors to Heart Failure with Preserved or Re-duced Ejection Fraction: Insights from the Framingham Heart Study of the National Heart, Lung and Blood Institute. Circulation, 119, 3070-3077. [Google Scholar] [CrossRef]
|
|
[4]
|
Iyngkaran, P., Liew, D., Neil, C., Driscoll, A., Marwick, T.H. and Hare, D.L. (2018) Moving from Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients with Multiple Comorbidities and Older Age. Clinical Medicine Insights: Cardiology, 12. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Lala, A., Mcnulty, S.E., Mentz, R.J., et al. (2015) Relief and Re-currence of Congestion during and after Hospitalization for Acute Heart Failure: Insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute De-compensated Heart Failure (CARESS-HF). Circulation: Heart Failure, 8, 741-748. [Google Scholar] [CrossRef]
|
|
[6]
|
Jessup, M., Marwick, T.H., Ponikowski, P., Voors, A.A. and Yancy, C.W. (2016) 2016 ESC and ACC/AHA/HFSA Heart Failure Guideline Update—What Is New and Why Is It Important? Nature Reviews Cardiology, 13, 623-628. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Yancy, C.W., Jessup, M., Bozkurt, B., et al. (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology, 70, 776-803. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Zhang, Y., Zhang, J., Butler, J., et al. (2017) Contemporary Epide-miology, Management and Outcomes of Patients Hospitalized for Heart Failure in China: Results from the China Heart Failure (China-HF) Registry. Journal of Cardiac Failure, 23, 868-875. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
冯盼盼. 沙库巴曲缬沙坦治疗LVEF ≥ 40%心力衰竭患者的疗效研究[D]: [硕士学位论文]. 西安: 西安医学院, 2020.
|
|
[10]
|
董浩, 门素珍, 马丽娟, 孙孟华, 卢晶晶, 刘巍. 利钠肽系统与肾素-血管紧张素-醛固酮系统在心力衰竭中交互作用[J]. 现代生物医学进展, 2017, 17(13): 2578-2581.
|
|
[11]
|
李小岩, 李华容, 陈邦超, 等. 伊伐布雷定对2型糖尿病合并心力衰竭患者的心率变应性及TNF-α、IL-6、CRP水平的影响[J]. 国际检验医学杂志, 2020, 41(7): 873-876.
|
|
[12]
|
曹梦灵, 孙春金, 关宏锏, 等. T淋巴细胞亚群在心力衰竭中的作用机制及诊疗进展[J]. 中国心血管病研究, 2021, 19(2): 164-168.
|
|
[13]
|
Katz, A.M. (2008) The “Modern” View of Heart Failure: How Did We Get Here? Circulation: Heart Failure, 1, 63-71. [Google Scholar] [CrossRef]
|
|
[14]
|
Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. (2016) Executive Summary: Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart As-sociation. Circulation, 133, 447-454. [Google Scholar] [CrossRef]
|
|
[15]
|
Yusuf, S., The, S.I. and Investigators, S. (1991) Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. The New England Journal of Medicine, 325, 293-302. [Google Scholar] [CrossRef]
|
|
[16]
|
Mcmurray, J.J.V., Packer, M., Desai, A.S., et al. (2014) Angiotensin—Neprilysin Inhibition versus Enalapril in Heart Failure. The New England Journal of Medicine, 371, 993-1004. [Google Scholar] [CrossRef]
|
|
[17]
|
Gu, J., Noe, A., Chandra, P., Al-Fayoumi, S., Li-gueros-Saylan, M., Sarangapani, R., Maahs, S., Ksander, G., Rigel, D.F., Jeng, A.Y., Lin, T.-H., Zheng, W. and Dole, W.P. (2009) Pharmacokinetic and Pharmacodynamic Properties of LCZ696, a Novel Dual-Acting Angiotensin Receptor Neprilysin Inhibitor (ARNI). The Journal of Clinical Pharmacology, 50, 401-414. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Volpe, M. (2014) Natriuretic Peptides and Cardio-Renal Disease. International Journal of Cardiology, 176, 630-639. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Hayashi, D., Kudoh, S., Shiojima, I., et al. (2004) Atrial Natriu-retic Peptide Inhibits Cardiomyocyte Hypertrophy through Mitogen-Activated Protein Kinase Phosphatase-1. Biochemi-cal and Biophysical Research Communications, 322, 310-319. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Calderone, A., Thaik, C.M., Takahashi, N., Chang, D.L. and Co-lucci, W.S. (1998) Nitric Oxide, Atrial Natriuretic Peptide and Cyclic GMP Inhibit the Growth-Promoting Effects of Norepinephrine in Cardiac Myocytes and Fibroblasts. The Journal of Clinical Investigation, 101, 812-818. [Google Scholar] [CrossRef]
|
|
[21]
|
Piek, E., Ju, W.J., Heyer, J., et al. (2001) Functional Characterization of Transforming Growth Factor β Signaling in Smad2- and Smad3-Deficient Fibroblasts. The Journal of Biological Chem-istry, 276, 19945-19953. [Google Scholar] [CrossRef]
|
|
[22]
|
Kapoun, A.M., Liang, F., O’Young, G., Damm, D.L., Quon, D., White, R.T., Munson, K., Lam, A., Schreiner, G.F. and Protter, A.A. (2004) B-Type Natriuretic Peptide Exerts Broad Functional Opposition to Transforming Growth Factor-β in Primary Human Cardiac Fibroblasts: Fibrosis, Myofibroblast Conversion, Proliferation and Inflammation. Circulation Research, 94, 453-461. [Google Scholar] [CrossRef]
|
|
[23]
|
Izumiya, Y., Araki, S., Usuku, H., Rokutanda, T., Hanatani, S. and Ogawa, H. (2012) Chronic C-Type Natriuretic Peptide Infusion Attenuates Angiotensin II-Induced Myocardial Superoxide Production and Cardiac Remodeling. International Journal of Vascular Medicine, 2012, Article ID: 246058. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Lisy, O., Jougasaki, M., Schirger, J.A., et al. (1998) Neutral Endopeptidase Inhibition Potentiates the Natriuretic Actions of Adrenomedullin. American Journal of Physiology Renal, Fluid and Electrolyte Physiology, 275, F410-F414. [Google Scholar] [CrossRef]
|
|
[25]
|
Rademaker, M.T., Charles, C.J., Cooper, G.J.S., Coy, D.H., Espiner, E.A., Lewis, L.K., Nicholls, M.G. and Richards, A.M. (2002) Combined Endopeptidase Inhibition and Adre-nomedullin in Sheep with Experimental Heart Failure. Hypertension, 39, 93-98. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
高扬, 栾波, 高尧, 等. 沙库巴曲/缬沙坦治疗慢性心力衰竭的临床观察[J]. 中国循证心血管医学杂志, 2019, 11(5): 595-597.
|
|
[27]
|
Ademi, Z., Pfeil, A.M., Hancock, E., et al. (2017) Cost-Effectiveness of Sacubitril/Valsartan in Chronic Heart-Failure Patients with Reduced Ejection Fraction. Swiss Med-ical Weekly, 147, w14533.
|
|
[28]
|
Solomon, S.D., Pfeffer, M.A., Pocock, S., et al. (2008) Response to Letter Regarding Article, “Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients with Chronic Heart Failure”. Circulation, 118, e8. [Google Scholar] [CrossRef]
|
|
[29]
|
Tsutsui, H., Momomura, S., Saito, Y., Ito, H., et al. (2017) Efficacy and Safety of Sacubitril/Valsartan (LCZ696) in Japanese Patients with Chronic Heart Failure and Re-duced Ejection Fraction: Rationale for and Design of the Randomized, Double-Blind PARALLEL-HF Study. Journal of Cardiology, 70, 225-231. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Canu, A., Hebert, M., Gachet, A., Arabucki, F., Maurin, V., Picard, F. and Dos Santos, P. (2017) Results of a Single Center Experience on 110 Consecutive Patients Treated with Entresto (Sacubitril/Valsartan). Archives of Cardiovascular Diseases Supplements, 9, 33. [Google Scholar] [CrossRef]
|
|
[31]
|
Lamaida, N. and Cerciello, A.J.E.H.J.S. (2021) 155 Effects on Sacubitril/Valsartan on Natriuretic Peptides in Patients with a Reduced Ejection Fraction. European Heart Journal Supplements, 23. [Google Scholar] [CrossRef]
|
|
[32]
|
Morrow, D.A., Velazquez, E.J., Devore, A.D., et al. (2019) Cardiovascular Biomarkers in Patients with Acute Decompensated Heart Failure Randomized to Sacubitril-Valsartan or Enalapril in the PIONEER-HF Trial. European Heart Journal, 40, 3345-3352. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Cleland, J.G.F., Tendera, M., Adamus, J., Freemantle, N., Gray, C.S., Lye, M., O’Mahony, D., Polonski, L., Taylor, J., on Behalf of the PEP Investigators (1999) Perindopril for Elderly Peo-ple with Chronic Heart Failure: The PEP-CHF Study. European Journal of Heart Failure, 1, 211-217. [Google Scholar] [CrossRef]
|
|
[34]
|
Ksander, G.M., Ghai, R.D., De Jesus, R., Diefenbacher, C., Yuan, A., Berry, C., Sakane, Y. and Trapani, A. (1995) Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors. Journal of Medicinal Chemistry, 38, 1689-1700. [Google Scholar] [CrossRef]
|
|
[35]
|
Feng, L., Karpinski, P.H., Sutton, P., et al. (2012) LCZ696: A Dual-Acting Sodium Supramolecular Complex. Tetrahedron Letters, 53, 275-276. [Google Scholar] [CrossRef]
|
|
[36]
|
Solomon, S.D.P.D., Zile, M.P., Pieske, B.P., et al. (2012) The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase 2 Dou-ble-Blind Randomised Controlled Trial. The Lancet, 380, 1387-1395. [Google Scholar] [CrossRef]
|
|
[37]
|
文和, 邱继欢, 胡朗, 等. 沙库巴曲缬沙坦治疗射血分数中间值心力衰竭患者的临床疗效[J]. 心脏杂志, 2020, 32(2): 135-139.
|
|
[38]
|
Neeland, I.J.M.D., Patel, R.S.M.D., Eshtehardi, P.M.D., et al. (2012) Coronary Angiographic Scoring Systems: An Evaluation of Their Equivalence and Va-lidity. The American Heart Journal, 164, 547-552. e1. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Zhang, H.-W., Jin, J.-L., Cao, Y.-X., et al. (2021) Association of Small Dense LDL-Cholesterol with Disease Severity, Hypertension Status and Clinical Outcome in Patients with Coro-nary Artery Disease. Journal of Hypertension, 39, 511-518. [Google Scholar] [CrossRef]
|
|
[40]
|
董有正. 沙库巴曲缬沙坦用于急性前壁ST段抬高型心肌梗死PCI术后患者的安全性及疗效研究[D]: [硕士学位论文]. 南昌: 南昌大学, 2021.
|
|
[41]
|
Meagher, P., Adam, M., Civitarese, R., Bugyei-Twum, A. and Connelly, K.A. (2018) Heart Failure with Preserved Ejection Fraction in Diabetes: Mechanisms and Management. Canadian Journal of Cardiology, 34, 632-643. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Johansson, I., Dahlström, U., Edner, M., Näsman, P., Rydén, L. and Norhammar, A. (2018) Type 2 Diabetes and Heart Failure: Characteristics and Prognosis in Preserved, Mid-Range and Reduced Ventricular Function. Diabetes & Vascular Disease Research, 15, 494-503. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Kompa, A.R., Lu, J., Weller, T.J., et al. (2018) Angiotensin Re-ceptor Neprilysin Inhibition Provides Superior Cardioprotection Compared to Angiotensin Converting Enzyme Inhibition after Experimental Myocardial Infarction. International Journal of Cardiology, 258, 192-198. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Trivedi, R.K., Polhemus, D.J., Li, Z., et al. (2018) Combined An-giotensin Receptor—Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure. Journal of the American Heart Association, 7, e008268. [Google Scholar] [CrossRef]
|
|
[45]
|
Bö, M., Ruilope, L.M., Lacourciere, Y., Dukat, A., Gong, J. and Lefkowitz, M. (2010) Blood Pressure Reduction with the Novel Dual-Acting Angiotensin Receptor Neprilysin Inhibitor LCZ696: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Active-Comparator Study. Journal of the American College of Cardiology, 55, A61.E584. [Google Scholar] [CrossRef]
|
|
[46]
|
Kario, K., Sun, N., et al. (2014) Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients with HypertensionNovelty and Significance. Hypertension, 63, 698-705. [Google Scholar] [CrossRef]
|
|
[47]
|
Martens, P., Nuyens, D., Rivero-Ayerza, M., et al. (2019) Sacubitril/Valsartan Reduces Ventricular Arrhythmias in Parallel with Left Ventricular Reverse Remodeling in Heart Failure with Reduced Ejection Fraction. Clinical Research in Cardiology, 108, 1074-1082. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Jing, W., Vaziri, N.D., Nunes, A., et al. (2017) LCZ696 (Sacu-bitril/Valsartan) Ameliorates Oxidative Stress, Inflammation, Fibrosis and Improves Renal Function beyond Angiotensin Receptor Blockade in CKD. American Journal of Translational Research, 9, 5473-5484.
|
|
[49]
|
Spannella, F., Marini, M., Giulietti, F., et al. (2019) Renal Effects of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: A Real Life 1-Year Follow-Up Study. Internal and Emergency Medicine, 14, 1287-1297. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Andersen, S., Axelsen, J.B., Ringgaard, S., et al. (2019) Effects of Combined Angiotensin II Receptor Antagonism and Neprilysin Inhibition in Experimental Pulmonary Hypertension and Right Ventricular Failure. International Journal of Cardiology, 293, 203-210. [Google Scholar] [CrossRef] [PubMed]
|